BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:petrelintide readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of petrelintide\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07682818-162@assetmemo.bio
DTSTAMP:20261121T004543Z
DTSTART;VALUE=DATE:20270412
DTEND;VALUE=DATE:20270413
SUMMARY:petrelintide: Phase 1 readout est. (NCT07682818)
DESCRIPTION:petrelintide\, phase 1.\nStudy: Pharmacokinetics of Petrelintid
 e in Participants With Impaired Hepatic Function\nEstimated primary comple
 tion: 12 April 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 petrelintide#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07682818
URL:https://assetmemo.bio/drug/petrelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07589686-162@assetmemo.bio
DTSTAMP:20261121T004543Z
DTSTART;VALUE=DATE:20271112
DTEND;VALUE=DATE:20271113
SUMMARY:petrelintide: Phase 2 readout est. (NCT07589686)
DESCRIPTION:petrelintide\, phase 2\, Obesity.\nStudy: A Dose-Finding Study 
 of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Ove
 rweight\nEstimated primary completion: 12 November 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/petrelintide#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07589686
URL:https://assetmemo.bio/drug/petrelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07843485-162@assetmemo.bio
DTSTAMP:20261121T004543Z
DTSTART;VALUE=DATE:20281020
DTEND;VALUE=DATE:20281021
SUMMARY:petrelintide: Phase 3 readout est. (NCT07843485)
DESCRIPTION:petrelintide\, phase 3\, Obesity.\nStudy: A Phase III Study to 
 Evaluate the Efficacy and Safety of Petrelintide in Participants With Over
 weight or Obesity and Type 2 Diabetes\nEstimated primary completion: 20 Oc
 tober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/petrelint
 ide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07843485
URL:https://assetmemo.bio/drug/petrelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07843498-162@assetmemo.bio
DTSTAMP:20261121T004543Z
DTSTART;VALUE=DATE:20281221
DTEND;VALUE=DATE:20281222
SUMMARY:petrelintide: Phase 3 readout est. (NCT07843498)
DESCRIPTION:petrelintide\, phase 3\, Obesity.\nStudy: A Phase III Study to 
 Evaluate the Efficacy and Safety of Petrelintide in Participants With Over
 weight or Obesity\nEstimated primary completion: 21 December 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/petrelintide#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07843498
URL:https://assetmemo.bio/drug/petrelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07843472-162@assetmemo.bio
DTSTAMP:20261121T004543Z
DTSTART;VALUE=DATE:20300728
DTEND;VALUE=DATE:20300729
SUMMARY:petrelintide: Phase 3 readout est. (NCT07843472)
DESCRIPTION:petrelintide\, phase 3\, Obesity.\nStudy: A Phase III Study to 
 Evaluate the Efficacy and Safety of Petrelintide in Participants With Over
 weight or Obesity and Established Cardiovascular Disease\nEstimated primar
 y completion: 28 July 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/petrelintide#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07843472
URL:https://assetmemo.bio/drug/petrelintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
